

F. No. ND/MA/23/000086
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

Tele.No.011-23236965
Fax.No.011-23236973

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated:

To

M/s Sun Pharma Laboratories Limited,
Sun Pharma Advanced Research Centre (SPARC),
Tandalja, Vadodara – 390012, Gujarat, INDIA

Subject: Application for permission to conduct “A Multicenter, Randomized, Assessor-blind, Parallel-group, Phase III, Active-control Comparative Study to Evaluate the Efficacy and Safety of Lumateperone in Comparison to Quetiapine for the Treatment of Bipolar II Depression.”—regarding.

Sir,

With reference to your application no. **ND/CT21/FF/2023/37407** dated **04.05.2023**; please find enclosed herewith the permission in **Form CT-06, No. CT/ND/34/2023** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

RAJEEV SINGH
RAGHUVANS
HI
(Dr. Rejeev Singh Raghuvanshi)
Central Licensing Authority

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI,
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27
69041015a06564fe67f54b765db1cb,
postalCode=600034, st=TAMIL NADU,
serialNumber=12345678901234567890,
cn=RAJEEV SINGH RAGHUVANSHI

Conditions of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of

- receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
 - (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
 - (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
 - (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
 - (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
 - (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL
NEW DRUG**

The Central Licensing Authority hereby permits **M/s Sun Pharma Laboratories Limited, Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara – 390012, Gujarat, INDIA. Tel. : (91-265) 661 5500 Fax : (91-265) 235 4897** to conduct clinical trial of the new drug as per Protocol Number: **ICR/22/004, Version No. 2.0 dated 30th June 2023** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug or investigational new drug:	Lumateperone capsules 42 mg	
Therapeutic class:	Atypical antipsychotic	
Dosage form:	Capsules	
Composition:	Each capsule contains: Lumateperone Tosylate equivalent to Lumateperone.....42 mg Excipients.....q.s Approved colours used in capsule shell	
Indications:	Indicated for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.	
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
1	Dr. Dhananjay Chaudhari (Professor and Head of Department) Department of Psychiatry, GSVM Medical College, Kanpur	Ethics Committee GSVM Medical College, Kanpur ECR/680/Inst/UP/2014/RR-20
2	Dr. Asish Mukhopadhyay (Professor and Head of Department) Department of Psychiatry, Nil Ratan Sircar Medical College and Hospital, Kolkata	Ethics Committee Government, N.R.S. Medical College and Hospital, Kolkata ECR/609/Inst/WB/2014/RR-20
3	Dr. Ashutosh Kumar (Assistant Professor) Department of Psychiatry, S.N Medical College and Hospital, Agra	Institutional Ethics Committee S.N Medical College, Agra ECR/1409/Inst/UP/2020

4	Dr Pradhyuman Jeshingbhai Chaudhary (Assistant Professor) Department of Psychiatry, GMERS Medical College and Civil Hospital, Ahmedabad	Institutional Ethics Committee, GMERS Medical College, Ahmedabad ECR/404/Inst/GJ/2013/RR-20
5	Dr. Dharmesh V Patel (Psychiatrist) GCS, Medical College Hospital and Research Centre, Ahmedabad	IEC, GCS Medical College, Hospital and Research Centre, Ahmedabad ECR/339/Inst/GJ/2013/RR-19
6	Dr. Gopalakrishnan Ganesan (Consultant Psychiatrist) Medstar Speciality Hospital, Bangalore	Medstar Speciality Hospital Ethics Committee, Bangalore ECR/1324/Inst/KA/2019
7	Dr. Neeli Uma Jyothi (Professor and Head of Department) Department of Psychiatry, Government General Hospital, Guntur	ETHICS COMMITTEE Guntur Medical College and Government General Hospital, Guntur ECR/467/Inst/AP/2013/RR-19
8	Dr. Praveen Kumar Rayavar Sathyam (Associate Professor) Department of Psychiatry, Panimalar Medical College Hospital and Research Institute, Chennai	PMCHRI-IHEC, Panimalar Medical College Hospital and Research Institute, Chennai ECR/1399/Inst/TN/2020
9	Dr. Bhirud Mahesh Govindrao (Consultant Psychiatrist) Dhadiwal Hospital in coalition with Shreeji Healthcare, Nasik	Shree Institutional Ethics Committee, Dhadiwal Hospital in coalition with Shreeji Healthcare, Nashik ECR/1149/Inst/MH/2018 /RR-21
10	Dr. Mistry Kalrav Harenbhai (Consultant Psychiatrist) PHC-Prajna Health care, Ahmedabad	Medilink Ethics Committee, Ahmedabad ECR/344/Inst/GJ/2013/RR-19

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

RAJEEV SINGH
Digitally signed by RAJEEV SINGH RAGHUVANSHI
 DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
 ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
 2.5.4.20=80c62f6a23e4eafbea239774cdeb03c2769041
 015a06564fee7f54b765db1cb, postalCode=600034,
 st=TAMIL NADU,
 email=rajeev.singh@cdsc.gov.in, serial=F03BDC902D0E1FE
 753E172A76120E6A6A570112A77B013, cn=RAJEEV
 SINGH RAGHUVANSHI
Central Licensing Authority
Stamp

New Delhi

Date: